Compare TOL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | DVA |
|---|---|---|
| Founded | 1967 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 14.9B |
| IPO Year | 1994 | 2003 |
| Metric | TOL | DVA |
|---|---|---|
| Price | $148.63 | $180.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | ★ $164.44 | $156.75 |
| AVG Volume (30 Days) | 686.0K | ★ 960.3K |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 4.91 | ★ 6.86 |
| Revenue | $7,143,258,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | $6.01 | $3.07 |
| P/E Ratio | $30.19 | ★ $26.25 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $123.15 | $101.00 |
| 52 Week High | $168.36 | $247.49 |
| Indicator | TOL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 31.99 |
| Support Level | $143.89 | $176.59 |
| Resistance Level | $154.52 | $202.63 |
| Average True Range (ATR) | 3.86 | 4.64 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 65.76 | 48.75 |
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder within the US according to total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.